China approves two domestically developed COVID drugs

Simcere Pharmaceutical

29/01/2023 09:46

BEIJING, Jan 29 (Reuters) - China has approved two
domestically developed oral medicines for COVID-19 patients with
mild symptoms, the National Medical Products Administration said
on Sunday.
     The drugs, used for treating adult patients with mild to
moderate COVID-19 infections, have been developed by Simcere
Pharmaceutical Group <2096. HK> and a unit of Shanghai Junshi
Biosciences Co Ltd  688180.SS , the administration said in a
statement on its website.
    China abandoned its stringent "zero COVID" policy in early
December after protests against it, allowing people to travel
and the virus to spread rapidly throughout the country, boosting
demand for COVID treatments.
 (Reporting by Kevin Yao; Editing by Muralikumar Anantharaman)
 ((kevin.yao@thomsonreuters.com; +8610 5669 2128;))